

## Temerty Medicine 2022 Grant Writing & Research Resources Workshop

## **Future Funding Streams**

Wednesday, June 15, 2022

Office of the Vice Dean, Research & Health Science Education

Temerty Medicine

# Welcome!

• 9:00 am Welcome – Justin Nodwell, Vice Dean, research & Health Science Education (5 mins)

- 9:05 am Panel Discussion: How to incorporate EDI into grant proposals (50 mins)
- Panel Members;
  - Dr. Nicole Kaniki, Director of Equity, Diversity and Inclusion, VPRI
  - Dr. Bojana Stefanovic, Dept. of Medical Biophysics
  - Dr. Karl Zabjek, Dept. of Physical Therapy
- 9:55 am Additional time for Q&A (10 mins)
- 10:05 am Future funding streams (10 mins) Joanna King
- 10:15 am Temerty Medicine Core Facilities Update (10 mins) Betty Poon
- 10:25 am Grant Fundamentals (45 minutes) Golnaz Farhat & Alex De Serrano
- 11:10 am Q&A (15 minutes)

# Future Funding Streams

- Pathway Grants
- Temerty Knowledge Translation
- EPIC Funding Opportunities
- Temerty Research Excellence Award
- Industrial Partnerships Officer

# Pathway Grants

4

Pathway Grants function as an internal CIHR bridge grant for top-rated Project Grant proposals from on-campus Temerty Faculty of Medicine applicants:

• Up to 6 grants per Project competition (Spring and Fall) of \$50,000 for 1 year, with a potential 1-year no-cost extension.

• The top 6 eligible unfunded proposals, determined by percentile rank within their committee, will receive Pathway Grants



# Pathway Grants

To be eligible for a Pathway Grant – you must be a member of the <u>Temerty Faculty</u> of <u>Medicine's College of Internal Scientific</u> <u>Reviewers</u> at the point the grant is submitted to the CIHR Project Grant competition **and** submit your application for Internal Peer Review.

- You must have your grant reviewed in order to be eligible.
- A PI can hold no more than **two** active Pathway Grants at one time.



# Pathway Grants

- Results from the Spring 2022 CIHR Project Grant competition will be announced in July 2022.
- Pathway Grants winners will be contacted shortly after.

6

• Dates and details for the Fall 2022 Project Grant internal peer review process will be released soon.



## Temerty Knowledge Translation Grants

• There have been two previous competitions;

- The Development of Novel Antibody Tools for COVID-19 Diagnosis or Immunotherapies (Spring 2021)
- Addressing health inequities in disadvantaged populations (Summer 2021)
- A third competition will be held in 2022/23

 The theme, dates and eligibility details for the third round will be shared via the <u>What's</u> <u>New in Research Funding</u> newsletter



EPPC Emerging & Pandemic Infections Consortium

# DEFY GRAVITY

ACADEMIC DIRECTOR: SCOTT GRAY-OWEN, PH.D.

DIRECTOR, STRATEGY & PARTNERSHIPS: NATASHA CHRISTIE-HOLMES, PH.D.



## **EPIC** PILLARS AND APPROACH


EPIC WILL COORDINATE, LINK, AND SUPPORT CRITICAL SCIENTIFIC AND CLINICAL EXPERTISE THAT LEVERAGES THE IDL'S STATE-OF-THE-ART FACILITIES

VISION: An ecosystem of collaboration bringing together academic, government and industry scientists, engineers, clinicians, public health and policy experts to foster ground-breaking imagination around Four Pillars:

- 1. **Research** that is collaborative and attracts top talent in the area of infectious diseases
- 2. Training the next generation of infectious disease experts
- **3. Knowledge Translation** to accelerate the adoption of EPIC's innovations, support public policy, and increase public awareness
- 4. The **Infectious Disease Laboratories** will serve as a physical anchor and provide expert support for all network activities







Infection Countermeasures for Pandemic Preparedness



## **EPIC PILLARS & PROGRAMS**

С

#### **PILLAR 1. RESEARCH**

Program	Description
New Connections Grant	<ul> <li>Collaborative projects and support for early career researchers</li> <li>\$100,000/year</li> </ul>
Proof of Principle Grant	<ul> <li>Funds to test concepts and generate preliminary data</li> <li>Up to \$50,000/year</li> </ul>
Ideation Workshops	<ul> <li>Investigator-driven to convene researchers to explore potential ideas</li> <li>One in collaboration with Institute for Pandemics</li> </ul>
Global Scholars	<ul> <li>Visiting researchers from LMIC (will begin year 2)</li> </ul>





## **EPIC** PILLARS & PROGRAMS

#### **PILLAR 2. TRAINING AND TALENT**

Program	Description
Graduate Studentships	<ul> <li>Providing additional year of funding to successful Tri-Council funded students</li> <li>\$15,000/year</li> </ul>
PDF Fellowships	<ul> <li>Stipend + research allowance</li> <li>\$50,000/year; awarded for 2 year period</li> </ul>
Career Transition Award	<ul> <li>To senior PDF/RA for independent project</li> <li>\$120,00/year</li> </ul>
Interact Workshops	<ul> <li>Building connections across trainee network.</li> <li>Diverse topics: Regulatory/policy, Industrial partnerships and pipelines (quarterly)</li> </ul>
Trainee Mobility	Travel grants for partnership/training exchange

 $\boldsymbol{\wedge}$ 

DEFY

GRAVITY

11





## **EPIC** PILLARS & PROGRAMS

#### **PILLAR 3. KNOWLEDGE TRANSLATION**

Program	Description
Annual Symposium	<ul> <li>Present EPIC research</li> <li>Convene stakeholders from government, industry and academia</li> </ul>
Networking Events	<ul> <li>Infectious disease themed events based on Pillars of Health, KOL Practice Pitches, TR Talks</li> </ul>
Speaker Series	Toronto-wide, high impact lecture series with leading international authorities
Promotion and Communication	<ul> <li>Website development</li> <li>Strategic Partnership development</li> <li>Conference presence</li> <li>Media outreach</li> </ul>
Trainee Internships	MITACS / Industry supported

 $\boldsymbol{\wedge}$ 

DEFY

GRAVITY

12





# Temerty Research Excellence Award

• **Two** awards of \$5,000 each will be awarded to successful applicants.

• The winning applicants will **also** have their submission materials revised and submitted to an external award in the 12-month period following award competition.

• The external award will be selected in consultation with the applicant and the award review committee.

• Eligibility criteria and submission deadlines will be shared via the <u>What's</u> <u>New in Research Funding</u> newsletter





#### INDUSTRIAL PARTNERSHIPS OFFICER

#### ABOUT JARROD LADOUCEUR

- 8 years in post secondary institutions building programs to support commercialization and partnerships.
- Former national lead for AIMday. An international program designed to establish industry academic collaborations.
- Former member of the I-Inc steering committee. A network work 14 Canadian universities developing programs to support research commercialization.





- E-mail (reach out anytime) jarrod.Ladouceur@utoronto.ca
- New partnerships web page <u>https://temertymedicine.utoronto.ca/partnerships-0</u>
  - Office hours Quick 20min time sløts every Friday to connect with partnership staff from across UofT

Temerty Medicine

 Partnership updates – Bi-Monthly email updates with partnership opportunities, events, news (Coming soon: sign up on the partnerships webpage)

#### > HOW JARROD CAN HELP

- Connecting you with organizations
- · Advising on partnership options and policy
- Support creating new partnership programs and services
- Promoting opportunities to external organizations
- Helping you to navigate the partnership community in and around UofT.





# **Core Facilities and Services**

Betty Poon, Research Operations Officer betty.poon@utoronto.ca

June 15, 2022



- Dedicated management teams to provide specific technical expertise, training and protocol development assistance for research personnel
- Maximizing the impact of funding success to propel research at a Faculty-wide level and support future grant applications
- Supported through cost-recovery structures and strategic planning of grant-associated operational funding

https://medicine.utoronto.ca/core-facilities-services



### Division of Comparative Medicine (DCM)


- Director: Kerri Nielsen, DVM
- Manager: Frank Giuliano, RMLAT
- <u>http://www.dcm.utoronto.ca/</u>
- Federally and Provincially accredited Animal Care program at the Faculty of Medicine
- Preeminent veterinary technical staff including 4 Masters level animal technicians
- Over 25, 000 ft<sup>2</sup> dedicated to *in vivo* research, including germfree, gnotobiotics and SPF+ exclusion
- Multiple full animal imaging modalities on-site supported by dedicated technical expert






### Flow Cytometry Facility

- Director: Tania Watts, PhD
- Manager: Natalie Simard, PhD
- <u>http://flowcytometry.utoronto.ca/</u>



- Supported by dedicated operators with extensive FCM knowledge and over 20 years of experience
- Comprehensive training program partnership with WORK-FLOW for research personnel









### Microscopy Imaging Lab (MIL)

- Director: Stephen Girardin, PhD
- Manager: Lindsey Fiddes, PhD
- Consolidated microscopy core including confocal, fluorescence, scanning (SEM) and transmission (TEM) electron microscopes
- Expanding Cryo-EM capabilities
- Expert technical team trains research personnel in microscopy techniques and development of protocols
- Dedicated preparatory lab for SEM/TEM samples, Equipped for Cryo-TEM preparation
- Providing full-service microscopy (prep and scanning)





TEM of Vero cells infected with SARS-CoV-2, 120,000x (Isolated in C-CL3 Unit, Imaged by MIL) Banerjee et al, 2020



### Combined Containment Level 3 (C-CL3) Unit

- Director: Scott Gray-Owen, PhD
- Manager: Jessica Lam, MSc
- Federally licensed facilities for research involving RG3 pathogens
- Dedicated regulatory team providing guidance, validation and oversight
- Facilities for small animal *in vivo* studies and molecular *in vitro* research
- NEW! BDMelody FACS Cell Sorter, Luminex Multiplex, 10X Genomics Chromium Single-Cell RNA-Seq System







### Virology Core Lab and Biobank

- Director: Scott Gray-Owen, PhD
- Manager: Jessica Lam, MSc
- New, adaptive CL2+ space for viral research
- Foundational work on seasonal coronaviruses, HIV
- Extends TFoM infectious disease expertise to support other Faculties
- Leveraging opportunities for collaboration and building foundation for future studies on COVID-19 samples








### **Central Sterilization Service (CSS)**

- Providing glass-washing, laundry and sterilization services
- Centralized stock of glass and plasticware for all MSB researchers to access
- Multiple sterilization cycles daily allowing flexibility for lab schedules
- After-hours autoclaves available to trained users






### **TEMERTY FACULTY OF MEDICINE** UNIVERSITY OF TORONTO



#### Non-invasive (live & tissue) rodent imaging


IVIS & Bruker: 3D and 2D imaging of fluorescence/ bioluminescence and X-ray (high-def head, bone density

Leica Stereomicroscope: 3D epifluorescence,





#### Live/fixed cell imaging




nucleus Annexin V

Nikon Swept Field confocal & TIRF microscopes: 3D and 2D multicolour imaging.

Nikon Multi-photon microscope: Deep 3D and 2D multicolour imaging.

Annexin 11N6 cells



ο<sub>μM</sub> ThermoFisher □ H2O2 Cellomics: ■ <sup>100 µM</sup> Automated highthroughput multicolor imaging.



Core Facilities add value in grants

Build the foundation for early-stage investigators

• Established infrastructure, expertise and support

Show sustainability for established investigators

- Requested infrastructure can be well implemented
- Ongoing support for maintenance/operations

https://medicine.utoronto.ca/core-facilities-services



## **Grant-Writing Fundamentals**


June 15, 2022 Alex De Serrano & Golnaz Farhat

OFFICE OF THE VICE-DEAN, RESEARCH AND HEALTH SCIENCE EDUCATION



## What are the chances your grant gets funded?

Average National CIHR PG Success Rate



Your grant has to stand out in order for it to be funded

- The facts are not enough
- You need a strong sales pitch
- A compelling story

## **Common reasons grants are not funded**



- Weak impact and low significance
- Too ambitious / lacks focus
- Does not align with sponsor's priorities
- Does not adhere to application guidelines
- Too many gaps in logic
- Lacks appropriate expertise / not feasible
- Poorly written





## **Understand your audience**





- They are reviewing many proposals
- They are skeptical



## **Understand your audience**

"Who is my audience" is *the number one issue in grant writing*. Almost all grant panels are very heterogeneous. Therefore, you are usually writing for **intelligent researchers who are not experts in your area**, except for maybe **two to three experts**.

—"Tips for Good Grant Writing" CIHR






www.cihr-irsc.gc.ca/e/27491.htm#1.5

## **Understand your audience**


**Specialists**: researchers from your sub-field, with whom you share terminology and theoretical background

**Generalists**: researchers from the larger field or related fields





## Start by defining your Goals, Objectives and Hypothesis



## **Goals, Objectives, Hypothesis**

Our <u>long-term goal</u> is to find new strategies for remediating biofilm infections by addressing their physical properties.

This proposal's <u>objective</u> is to determine the role of the spatial structure and mechanics of biofilm infections on virulence, antibiotic resistance, and immune evasion.

Our <u>central hypothesis</u> is that spatial structure and mechanics are the major *physical* factors controlling the development of pathogenicity, antibiotic resistance, and immune evasion in biofilm infections.



8

## The specific aims are the backbone of your proposal

They should:

- Be specific
- Use strong verbs
- Use accessible language
- Be related but not interdependent
- Allow for multiple possible outcomes



## The specific aims are the backbone of your proposal

## They should:

- Be specific and descriptive
- Use strong verbs
- Use accessible language
- Be related but not interdependent
- Allow for multiple possible outcomes

"Investigate biofilm-immune system interactions."

"<u>Determine</u> the impact of biofilm spatial structure and mechanics on the ability of biofilms to evade neutrophils."



## **Specific Aims**


Aim 1. <u>Characterize</u> the spatial structure (size and number density of bacterial aggregates) and mechanics (viscoelastic properties) of biofilm infections in wounds.

**Aim 2.** <u>Measure</u> the impact of biofilm spatial structures on bacterial growth, biofilm microenvironment development, antibiotic resistance, and virulence.

Aim 3. <u>Determine</u> the impact of biofilm spatial structure and mechanics on the ability of biofilms to evade neutrophils.


11

Two questions drive the reviewers' decision





Two questions drive the reviewers' decision







# **Make Your First Page Impactful**

#### Significance of the problem

#### Goals, Objectives, Hypothesis

#### Aims

#### Impact

#### Significance and Impact of Research

Annually, chronic infections affect 17 million Americans, cause at least 550,000 American deaths, and cost the US healthcare system billions of dollars [1-8]. Chronic bacterial infections often resist antibiotics and evade the host immune defense [10, 15-18], making them resistant to treatment. Most of these treatment-resistant infections are caused by biofilms, aggregated bacteria that are embedded in a matrix of polymer and protein. Unlike well-mixed, liquid cultures, biofilm infections have well-defined spatial structure, which is determined by bacteria traits (size and position of aggregates) and matrix heterogeneity. Matrix polymers and proteins also confer intercellular cohesion on biofilm bacteria, which affects mechanical resistance of the biofilm to physical breakup. The impact of spatial structure and matrix mechanics on biofilm properties, such as virulence, antibiotic resistance, and immune evasion are largely unknown. Indeed, we know little about what specific structures are largely lacking. Because current biofilm treatments, which target genes or specific bacteria, have proven ineffective [55], new approaches that integrate knowledge of the physical properties of biofilms are needed.

As such, our **long-term goal** is to find new strategies for remediating biofilm infections by addressing physical properties.

This proposal's **objective** is to determine the role of the spatial structure and mechanics of biofilm infections on virulence, antibiotic resistance, and immune evasion.

Here, our **central hypothesis** is that spatial structure and mechanics are the major *physical* factors controlling the development of pathogenicity, antibiotic resistance, and immune evasion in biofilm infections. This hypothesis is based on a synthesis of our own and others' published work.

We will test our central hypothesis and attain our objective via the following specific aims:

Aim 1. Characterize the spatial structure (size and number density of bacterial aggregates) and mechanics (viscoelastic properties) of biofilm infections in wounds.

Aim 2. Measure the impact of biofilm spatial structures on bacterial growth, biofilm microenvironment development, antibiotic resistance, and virulence.

Aim 3. Determine the impact of biofilm spatial structure and mechanics on the ability of biofilms to evade neutrophils.

The **expected outcome** of this work is a comprehensive understanding of what structures and mechanics develop in biofilm infection of chronic wounds, and the degree to which these structures and mechanics give rise to pathogenicity, antibiotic resistance, and evasion of the immune system. The results will have an important *positive impact* because they lay the groundwork to develop a new class of targeted treatments.

# The first paragraph provides context

Context is:

"the circumstances that form the setting for an event, statement, or idea, and in terms of which it can be fully <u>understood</u> and <u>assessed</u>"

- Helps the reviewer understand and relate to the problem
- Makes your work relevant and current
- Through story-telling, plays on the reviewer's emotions





# Use storytelling to engage the reviewer

'Story' is the concept that should underlie the structure of the entire proposal. The clearer and simpler, the more engrossing it is.

[This] will give the **generalist** a context in which to understand the significance of the work, but **fellow specialists** will also appreciate [it].





--- "Elements of Style," Nature Physics 3.9 (2007): 581



17

Annually, chronic infections affect 17 million Americans, cause at least 550,000 American deaths, and cost the US healthcare system billions of dollars [1-8]. Chronic bacterial infections often resist antibiotics and evade the host immune defense [10, 15-18], making them resistant to treatment. Most of these treatment-resistant infections are caused by biofilms, aggregated bacteria that are embedded in a matrix of polymer and protein. Unlike well-mixed, liquid cultures, biofilm infections have well-defined spatial structure, which is determined by bacteria traits (size and position of aggregates) and matrix heterogeneity. Matrix polymers and proteins also confer intercellular cohesion on biofilm bacteria, which affects mechanical resistance of the biofilm to physical breakup. The impact of spatial structure and matrix mechanics on biofilm properties, such as virulence, antibiotic resistance, and immune evasion are largely unknown. Indeed, we know little about what specific structures and mechanics develop in biofilm infections, and extant techniques to probe these properties are largely lacking. Because current biofilm treatments, which target genes or specific bacteria, have proven ineffective [55], new approaches that integrate knowledge of the physical properties of biofilms are needed.



Annually, chronic infections affect 17 million Americans, cause at least 550,000 American deaths, and cost the US healthcare system billions of dollars [1-8]. Chronic bacterial infections often resist antibiotics and evade the host immune defense [10, 15-18], making them resistant to treatment. Most of these treatmentresistant infections are caused by biofilms, aggregated bacteria that are embedded in a matrix of polymer and protein. Unlike well-mixed, liquid cultures, biofilm infections have well-defined spatial structure, which is determined by bacteria traits (size and position of aggregates) and matrix heterogeneity. Matrix polymers and proteins also confer intercellular cohesion on biofilm bacteria, which affects mechanical resistance of the biofilm to physical breakup.



Big picture

18



# The first paragraph sets up the hypothesis

Annually, chronic infections affect 17 million Americans, cause at least 550,000

American deaths, and cost the US healthcare system billions of dollars [1-8].

Chronic bacterial infections often resist antibiotics and evade the host immune defense [10] resistant in embedded biofilm infections. Big picture

Context for the Hypothesis

bacteria traits (size and position of aggregates) and matrix heterogeneity. Matrix

polymers and proteins also confer intercellular cohesion on biofilm bacteria, which

affects mechanical resistance of the biofilm to physical breakup.




Annually, chronic infections affect 17 million Americans, cause at least 550,000 American deaths, and cost the US healthcare system billions of dollars [1-8]. Chronic bacterial infections often resist antibiotics and evade the host immune **defense** [10, 15-18], making them resistant to treatment. Most of these treatmentresistant infections are caused by **biofilms**, aggregated bacteria that are embedded in a matrix of polymer and protein. Unlike well-mixed, liquid cultures, biofilm infections have well-defined **spatial structure**, which is determined by bacteria traits (size and position of aggregates) and matrix heterogeneity. Matrix polymers and proteins also confer intercellular cohesion on biofilm bacteria, which affects **mechanical resistance** of the biofilm to physical breakup.




Big picture

Context for the Hypothesis



Gap/Problem that the proposed project will solve





Gap/Problem that the proposed project will solve Why is the gap important?



# Goals et al. directly follow first paragraph

TEMERTY FACULTY OF MEDICINE UNIVERSITY OF TORONTO

#### First Paragraph of Proposal

#### Goals, Objectives, Hypothesis

### Aims

#### Impact

#### Significance and Impact of Research

Annually, chronic infections affect 17 million Americans, cause at least 550,000 American deaths, and cost the US healthcare system billions of dollars [1-8]. Chronic bacterial infections often resist antibiotics and evade the host immune defense [10, 15-18], making them resistant to treatment. Most of these treatment-resistant infections are caused by biofilms, aggregated bacteria that are embedded in a matrix of polymer and protein. Unlike well-mixed, liquid cultures, biofilm infections have well-defined spatial structure, which is determined by bacteria traits (size and position of aggregates) and matrix heterogeneity. Matrix polymers and proteins also confer intercellular cohesion on biofilm bacteria, which affects mechanical resistance of the biofilm to physical breakup. The impact of spatial structure and matrix mechanics on biofilm properties, such as virulence, antibiotic resistance, and immune evasion are largely unknown. Indeed, we know little about what specific structures are largely lacking. Because current biofilm treatments, which target genes or specific bacteria, have proven ineffective [55], new approaches that integrate knowledge of the physical properties of biofilms are needed.

As such, our **long-term goal** is to find new strategies for remediating biofilm infections by addressing physical properties.

This proposal's **objective** is to determine the role of the spatial structure and mechanics of biofilm infections on virulence, antibiotic resistance, and immune evasion.

Here, our **central hypothesis** is that spatial structure and mechanics are the major *physical* factors controlling the development of pathogenicity, antibiotic resistance, and immune evasion in biofilm infections. This hypothesis is based on a synthesis of our own and others' published work.

We will test our central hypothesis and attain our objective via the following specific aims:

Aim 1. Characterize the spatial structure (size and number density of bacterial aggregates) and mechanics (viscoelastic properties) of biofilm infections in wounds.

Aim 2. Measure the impact of biofilm spatial structures on bacterial growth, biofilm microenvironment development, antibiotic resistance, and virulence.

Aim 3. Determine the impact of biofilm spatial structure and mechanics on the ability of biofilms to evade neutrophils.

The **expected outcome** of this work is a comprehensive understanding of what structures and mechanics develop in biofilm infection of chronic wounds, and the degree to which these structures and mechanics give rise to pathogenicity, antibiotic resistance, and evasion of the immune system. The results will have an important *positive impact* because they lay the groundwork to develop a new class of targeted treatments.



## Convey significance and impact to engage the reviewer

- Chronic infections caused by biofilms annually affect 17 million Americans, cause at least 550,000
   American deaths, and cost the US healthcare system billions of dollars.
- Biofilm infection in chronic wounds afflicts both diabetic and non-diabetic patients and can lead to amputation.

socio-economic costs

evoke emotion





# Convey significance and impact to engage the reviewer

- Chronic infections caused by biofilms annually affect 17 million Americans, cause at least 550,000
   American deaths, and cost the US healthcare system billions of dollars.
- Biofilm infection in chronic wounds afflicts both diabetic and non-diabetic patients and can lead to amputation.
- Our work will provide novel insight into the structures and mechanics of *P. Aeruginosa*dominated biofilms—an important first step in developing therapeutics for patients with chronic wounds.
- The work proposed here will develop a platform of complementary techniques and knowledge that will be extensible to future studies of other infection sites and other organisms, including multispecies infections and engineered microbial consortia. This platform will be a foundational resource for the emerging field of physical microbiology & medicine.

socio-economic costs

evoke emotion

why fundamental knowledge is important

opens new doors

# Specificity adds credibility to impact statements

The more specific you are in your arguments, the more credible your arguments will be.

"This research will have a meaningful impact on...." OR

"This research will improve our understanding of the field of...."





# Specificity adds credibility to impact statements

The more specific you are in your arguments, the more credible your arguments will be.

"This research will have a meaningful impact on...." OR

"This research will improve our understanding of the field of ...."



"Characterizing the interaction between biofilm structure and

neutrophils opens up the possibility of manipulating biofilm structure



to counteract their evasion of the immune system."



Adapted from: https://www.niaid.nih.gov/sites/default/files/1-R01-AI121500-01A1 Gordon Application.pdf

Innovation


## Differentiate your approach from what has already been done.

The common approaches to developing new treatments for biofilms are either to find genes important for forming biofilms or to directly kill the bacteria in biofilms by novel drugs. These approaches most often fail to eradicate infections [55]. Our goal is to determine the structural and mechanical characteristics of biofilms and to identify the impact of these physical properties on disease course. Our innovative approach combines techniques from both biological and physical sciences and will elucidate the mechanistic relationship between the physical characteristics of biofilm infections and the course of biofilm disease, which are not accessible by conventional methods.

OLD approach why new approach is needed YOUR approach **INNOVATION** 




Two questions drive the reviewers' decision





# Approach: Writing your methods




Find a balance between excessive and necessary detail

Use accessible language to provide a rationale behind your methods

WHY






Remember, reviewers: • **DO NOT** want to replicate your methods

 DO want to understand WHY you chose a specific approach

# How to write the methods section

Specific Aim 1: Determine the spatial structure and mechanics of biofilm infections in chronic wounds







# Provide a rationale for methodological choices

Although artificial skin models have been used for studying wound healing, there are currently no good *in vitro* models for evaluating the host response to wound infection. For the experiments described in this proposal, <u>we will require a model that</u>, as closely as possible, <u>reflects the infection sequela seen in human wound patients</u>.

Rationale for using an approach





# Provide a rationale for methodological choices

Although artificial skin models have been used for studying wound healing, there are currently no good *in vitro* models for evaluating the host response to wound infection. For the experiments described in this proposal, <u>we will require a model</u> that, as closely as possible, <u>reflects the infection sequela seen in human wound patients</u>.

We will embed bacteria into gel beads, using both a WT and a highly-virulent strain, so that we can probe the interplay between phagocytosis timescale and virulence.

Rationale for using an approach

Rationale for a step



# Are you the right TEAM?

Listing publications and grants is not enough


- How does each member's expertise make them perfect for this project?
  - $_{\circ}\;$  be explicit; make the connections for reviewers
- How does your team come together to be more than the sum of its parts?
  - $_{\circ}~$  evidence of previous team successes
  - $_{\circ}$  synergies







# Do you have the right research ENVIRONMENT?



# Formatting

## 1. Break up the text

Headings and subheadings specified in the application

#### White space

Figures and tables

#### Significance and Impact of Research

Annually, chronic infections affect 17 million Americans, cause at least 550,000 American deaths, and cost the US healthcare system billions of dollars [1-8]. Chronic bacterial infections often resist antibiotics and evade the host immune defense [10, 15-18], making them resistant to treatment. Most of these treatment-resistant infections are caused by biofilms, aggregated bacteria that are embedded in a matrix of polymer and protein. Unlike well-mixed, liquid cultures, biofilm infections have well-defined spatial structure, which is determined by bacteria traits (size and position of aggregates) and matrix heterogeneity. Matrix polymers and proteins also confer intercellular cohesion on biofilm bacteria, which affects mechanical resistance of the biofilm to physical breakup. The impact of spatial structure and matrix mechanics on biofilm properties, such as virulence, antibiotic resistance, and immune evasion are largely unknown. Indeed, we know little about what specific structures and mechanics develop in biofilm treatments, which target genes or specific bacteria, have proven ineffective [55], new approaches that integrate knowledge of the physical properties of biofilms are needed.

As such, our long-term goal is to find new strategies for remediating biofilm infections by addressing physical properties.

This proposal's **objective** is to determine the role of the spatial structure and mechanics of biofilm infections on virulence, antibiotic resistance, and immune evasion.

Here, our **central hypothesis** is that spatial structure and mechanics are the major *physical* factors controlling the development of pathogenicity, antibiotic resistance, and immune evasion in biofilm infections. This hypothesis is based on a synthesis of our own and others' published work.

We will test our central hypothesis and attain our objective via the following specific aims:


Aim 1. Characterize the spatial structure (size and number density of bacterial aggregates) and mechanics (viscoelastic properties) of biofilm infections in wounds.

Aim 2. Measure the impact of biofilm spatial structures on bacterial growth, biofilm microenvironment development, antibiotic resistance, and virulence.

Aim 3. Determine the impact of biofilm spatial structure and mechanics on the ability of biofilms to evade neutrophils.

The **expected outcome** of this work is a comprehensive understanding of what structures and mechanics develop in biofilm infection of chronic wounds, and the degree to which these structures and mechanics give rise to pathogenicity, antibiotic resistance, and evasion of the immune system. The results will have an important *positive impact* because they lay the groundwork to develop a new class of targeted treatments.

### 2. Emphasize important points



#### Lists / Bullets

TEMERTY FACULTY OF MEDICINE

# Figures: DOs and DON'Ts





#### DON'T:

- Copy and paste figures or figure captions from a manuscript
- Use multi-panel figures

## DO:

- Keep figures simple
- Use a figure to illustrate an approach / scientific concept
- Present **select** preliminary results that support your approach
- Ensure text is legible at 100% magnification





# **Complex figures are challenging to navigate**

BSDomSub




Fig. 4: Gut microbiota compositions and unique taxa in Dom, Sub, and BS mice. a Alpha diversity of the gut microbiome of Dom, Sub, and background-strain (BS) mice (n = 20); SD = 26.10, 48.44, and 60.15, respectively). The alpha diversity of BS and Dom mice was not significantly different. **b** A principal component analysis showing the clustering of the gut microbiome of mice with the same social behavior phenotype. c A heatmap of the 100 most variant species identified; taxa with similar distributions are grouped together. d Relative abundance up to the genus level. Statistical significance was assessed by using a one-way ANOVA with Bonferroni correction, \*p < 0.05. Error bars show standard deviation.





Agranyoni, O. *et al.* Gut microbiota determines the social behavior of mice and induces metabolic and inflammatory changes in their adipose tissue. *npj Biofilms Microbiomes* **7**, 28 (2021).



40

# Use figures to describe a scientific concept





Figure 1 | **The development of bacterial biofilms from planktonic bacteria.** The pathway on the top depicts the development of non-surface-attached biofilms. These can, for example, form in chronic wounds or the lumen of the bronchi in patients with cystic fibrosis, where bacteria are not attached to a surface but instead embedded in mucus or other host material. The pathway below depicts surface-attached biofilms, where bacteria are attached to the surface of biomaterials such as implants or catheters. Blue circles represent susceptible bacteria and red circles represent tolerant bacteria.





# Use figures to illustrate your approach







# **Final thoughts and next steps**



# **Questions about grant-writing?**



a.deserrano@utoronto.ca golnaz.farhat@utoronto.ca

https://temertymedicine.utoronto.ca/grant-development

